Trial Profile

Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Lenalidomide
Indications Follicular lymphoma
Focus Therapeutic Use

Most Recent Events

12 Dec 2023 Results(n=154) presented at the 65th American Society of Hematology Annual Meeting and Exposition
26 Jun 2023 Status changed from active, no longer recruiting to discontinued. It was decided by the trial team to stop the collection of follow up data in trial SAKK 35/10.
25 Apr 2023 This trial has been discontinued in Denmark (global end date: 2023-01-27), according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com